第 1 到 11 筆結果,共 11 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2023 | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma | BANG-BIN CHEN ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH ; TSUNG-HAO LIU ; YING-CHUN SHEN ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | European radiology | 17 | 13 | |
2 | 2022 | Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma | SHIH-HUNG YANG ; JEN-CHIEH LEE ; BANG-BIN CHEN ; SUNG-HSIN KUO ; CHIUN HSU ; Bai, Li-Yuan | Frontiers in Immunology | 0 | 0 | |
3 | 2021 | Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials | BANG-BIN CHEN ; ZHONG-ZHE LIN ; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Cancers | 4 | 3 | |
4 | 2021 | Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma | BANG-BIN CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Diagnostics (Basel, Switzerland) | 7 | 7 | |
5 | 2020 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy | ZHONG-ZHE LIN ; BANG-BIN CHEN ; Hung, Yi-Ping; HUANG, PO-HSIANG ; Ying-Chun Shen ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG ; Lee, Rheun-Chuan; Chao, Yee; CHIUN HSU | Oncologist | 12 | 10 | |
6 | 2017 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy | YU-YUN SHAO ; BANG-BIN CHEN ; DA-LIANG OU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; Wang, M. J.; ANN-LII CHENG ; CHIUN HSU | Alimentary Pharmacology and Therapeutics | 10 | 8 | |
7 | 2017 | Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; PO-CHIN LIANG ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | European Radiology | 15 | 17 | |
8 | 2016 | Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; PO-CHIN LIANG ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Radiology | 27 | 25 | |
9 | 2015 | Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014) | CHIUN HSU ; BANG-BIN CHEN ; CHIEN-HUNG CHEN ; MING-CHIH HO ; CHIA-HSIEN CHENG ; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; ANN-LII CHENG | Liver Cancer | 17 | 22 | |
10 | 2014 | Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies | BANG-BIN CHEN ; I-LUN SHIH ; CHIH-HORNG WU ; CHIUN HSU ; CHIEN-HUNG CHEN ; TIFFANY TING-FANG SHIH ; KAO-LANG LIU ; PO-CHIN LIANG | Journal of Vascular and Interventional Radiology | 10 | 8 | |
11 | 2011 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil | CHAO-YU HSU ; Ying-Chun Shen ; CHIH-WEI YU ; CHIUN HSU ; Hu F.-C.; CHIH-HUNG HSU ; BANG-BIN CHEN ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Journal of Hepatology | 106 | 100 |